Technology
Health
Biotechnology
Magenta Therapeutics
$13.309876543210-$,.9876543210-$,.9876543210-$,.9876543210-$,.9876543210-$,.9876543210-$,.9876543210-$,.
$13.30
9
8
7
6
5
4
3
2
1
0
-
$
,
.
9
8
7
6
5
4
3
2
1
0
-
$
,
.
9
8
7
6
5
4
3
2
1
0
-
$
,
.
9
8
7
6
5
4
3
2
1
0
-
$
,
.
9
8
7
6
5
4
3
2
1
0
-
$
,
.
9
8
7
6
5
4
3
2
1
0
-
$
,
.
9
8
7
6
5
4
3
2
1
0
-
$
,
.
-$0.03 (-0.23%) Today
$0.00 (0.00%) As of 4:00 PM EDT after-hours
Why Robinhood?
You can buy or sell MGTA and other stocks, options, ETFs, and crypto commission-free!
About MGTA
Magenta Therapeutics, Inc. Common Stock, also called Magenta Therapeutics, is a clinical-stage biotechnology company, which engages in the development of novel medicines for bone marrow transplants. Read More It offers platform that focuses on critical areas of transplant medicine. The company was founded by David Scadden, Derrick Rossi, Alan Tyndall, Luigi Naldini, Robert Negrin, John F. Dipersio, and Jason Gardner in June 2015 and is headquartered in Cambridge, MA.
Employees
—
Headquarters
Cambridge, Massachusetts
Founded
2015
Market Cap
447.65M
Price-Earnings Ratio
—
Dividend Yield
—
Average Volume
120.60K
High Today
$13.63
Low Today
$13.08
Open Price
$13.46
Volume
29.11K
52 Week High
$21.00
52 Week Low
$5.31
Collections
Technology
Health
Biotechnology
Medical
Therapy
2018 IPO
US
North America
Price Paid on Robinhood
1% Higher
Right Now
52 Week Low
$5.31
Average Price Paid
$13.22
52 Week High
$21.00
MGTA Earnings
-$0.67
-$0.59
-$0.52
-$0.44
Q2 2018
Q3 2018
Q4 2018
Q1 2019
Q2 2019
Estimated
-$0.53 per share
Actual
Expected Aug 8, Pre-Market